The molecular characteristics of ischemic stroke with phlegm-heat syndrome and candidate biomarkers were identified based on multi-omics data. The main purpose of this study is to validate the molecular characteristics and biomarkers of phlegm-heat syndrome in ischemic stroke, and to demonstrate the association of biomarkers with clinical outcomes.
This is a cohort study in patients with acute ischemic stroke. The demographic characteristics, Traditional Chinese Medicine (TCM) syndromes, and other baseline information will be recorded. At the same time, baseline peripheral blood will be collected. These participants will be followed up to 90 days of onset, and 90-day modified Rankin scale (mRS) scores will be assessed. The collected blood samples will be tested by multi-factor detection technology for candidate biomarkers.
Study Type
OBSERVATIONAL
Enrollment
84
Guideline-based treatment includes anti-platelet therapy, control of vascular risk factors, and so on.
Dongzhimen Hospital
Beijing, Beijing Municipality, China
Sensitivity, specificity, and area under the ROC curve of molecular features of Phlegm-heat syndrome in ischemic stroke
Sensitivity, specificity, and area under the ROC curve of molecular features of Phlegm-heat syndrome in ischemic stroke. The molecular characteristics of phlegm-heat syndrome in ischemic stroke include but are not limited to matrix metalloproteinase 9, mitogen-activated protein kinase 1, interleukin 6, and tumor necrosis factor.
Time frame: Baseline
Proportion of patients independent
Proportion of patients independent is defined as the modified Rankin Scale score of 0, 1, or 2.
Time frame: 90 days
National Institute of Health Stroke Scale
The National Institute of Health Stroke Scale (NIHSS) ranges from 0 to 42, with higher scores indicating more severe neurological deficits.
Time frame: Baseline, 7 days and 10 days after stroke onset.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.